Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in large-cell lymphomas

B Coiffier1, E Lepage

  • 1Hematology Service, Hospices Civils de Lyon, France.

Leukemia & Lymphoma
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate?

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Involvement of the BCL2 Gene in 131 Cases of Non-Hodgkin's B Lymphomas: Analysis of Correlations with Immunological Findings and Cell Cycle.

Leukemia & lymphoma·2016
Same author

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Leukemia & lymphoma·2026
Same journal

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
See all related articles

This review identifies key prognostic factors for large cell lymphomas, including patient age, tumor characteristics, host-tumor interactions, and treatment details. Understanding these factors is crucial for predicting patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pathology

Background:

  • Large cell lymphomas are aggressive hematologic malignancies.
  • Accurate prognostic assessment is vital for guiding treatment strategies.
  • Identifying significant prognostic factors aids in patient stratification.

Purpose of the Study:

  • To review and categorize the most significant prognostic factors in large cell lymphomas.
  • To highlight factors with statistically significant correlations to patient outcomes.
  • To inform future prospective studies and therapeutic strategies.

Main Methods:

  • Literature review of prognostic factors in large cell lymphomas.
  • Categorization of factors into patient-related, tumor-related, host-tumor relationship, and physician-related groups.

Related Experiment Videos

  • Analysis of multiparametric studies to identify statistically significant correlations.

    • Main Results:

    • Prognostic factors include patient age, tumor stage, bulk, spread, extranodal sites, LDH, beta 2-microglobulin, performance status, B symptoms, albumin, interleukin levels, treatment type, and dose intensity.
    • Many factors are interrelated, with only a few maintaining statistical significance in multiparametric analyses.
    • Significant prognostic factors are essential for stratifying patients.

    Conclusions:

    • Prognostic factors in large cell lymphomas are diverse and complex.
    • Patient stratification based on key prognostic factors is recommended for future studies.
    • New therapeutic strategies should incorporate these validated prognostic indicators.